“Latest Stem Cells News”

A team of researchers at the UC Davis Institute for Regenerative Cures has developed a technique for using stem cells to deliver therapy that specifically targets the genetic abnormality found in Huntington’s disease, a hereditary brain disorder that causes progressive uncontrolled movements, dementia and death. The findings, now available online in the journal Molecular and Cellular Neuroscience, suggest a promising approach that might block the disease from advancing.

“For the first time, we have been able to successfully deliver inhibitory RNA sequences from stem cells directly into neurons, significantly decreasing the synthesis of the abnormal huntingtin protein,” said Jan A. Nolta, principal investigator of the study and director of the UC Davis stem cell program and the UC Davis Institute for Regenerative Cures. “Our team has made a breakthrough that gives families affected by this disease hope that genetic therapy may one day become a reality.”

Huntington’s disease can be managed with medications, but currently there are no treatments for the physical, mental and behavioral decline of its victims. Nolta and other experts think the best chance to halt the disease’s progression will be to reduce or eliminate the mutant huntingtin (htt) protein found in the neurons of those with the disease. RNA interference (RNAi) technology has been shown to be highly effective at reducing htt protein levels and reversing disease symptoms in mouse models.

“Our challenge with RNA interference technology is to figure out how to deliver it into the human brain in a sustained, safe and effective manner,” said Nolta, whose lab recently received funding from the California Institute for Regenerative Medicine to develop an RNAi delivery system for Huntington’s disease. “We’re exploring how to use human stem cells to create RNAi production factories within the brain.”

Incoming search terms:

Parkinson’s Disease – Medical world has struggled in finding permanent cure for this condition that usually affects men over the age of 50 years, but now this maybe changing with the advent of stem cell based research in regenerative medicine. A significant clinical human trial using these technique now seems feasible in the near future.

Stem Cells and its Potential:

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Stem cell therapy in Parkinson’s disease:

The race to find permanent cure for Parkinson’s disease seems to be on with many exciting and rapid developments taking place in stem cell based regenerative research. However on a cautious note it remains to be shown whether stem cell-derived dopamine neurons can efficiently reinnervate the regions of the brain like the striatum and provide functional recovery in Parkinson’s patients.

The transplantation of the human foetal midbrain tissue in animals and humans has provided knowledge of a number of requirements for establishing a clinically competitive Stem Cell-based therapy in Parkinson’s disease.

The stem cell grafts should:

1. Exhibit a regulated release of dopamine and molecular, electrophysiological, and morphological properties similar to those of substantia nigra neurons(substantianigra lies in the midbrain immediately dorsal to the cerebral peduncles);
2. Enable survival of more than 100,000 dopamine neurons per human putamen(round structure located at the base of the forebrain);
3. Re-establish the dopamine network within the striatum and restore the functional connectivity with host extra-striatal neural circuitries;
4. Reverse the motor deficits resembling human symptoms in animal models of Parkinson’s disease and induce long-lasting andmajor symptomatic relief in patients;
5. Produce no adverse-effects such as tumor formation, immune reactions and gastric disorders.

Incoming search terms:

Image via Wikipedia

Incoming search terms:

Dr Foteini Hassiotou has discovered stem cells can be obtained from breast milk

Serious and fatal diseases such as pancreatic cancer, Parkinson‘s disease and diabetes may eventually be treated using stem cells from breast milk following a remarkable discovery at the University of Western Australia.

UWA PhD student Foteini Hassiotou has potentially broken through the greatest hurdle in stem cell research – the ability to ethically obtain stem cells in a non-invasive manner.

Her finding that stem cells from breast milk can be directed to become other body cell types such as bone, fat, liver and brain cells, could reduce the need to use embryonic stem cells and therefore fast-track future therapies.

Dr Hassiotou’s research follows the 2008 discovery by a team of UWA scientists that breast milk contained embryonic-like stem cells.

Her work was boosted on Sunday when she won the AusBiotech-GlaxoSmithKline national student excellence award. She will now present her findings at an international conference.

Incoming search terms:

A notice for 8 million euros in funding for stem cell projects, a line of research that promises important results for ocular diseases, Parkinson’s, heart diseases, and the fight against tumors was announced by deputy health minister Ferruccio Fazio, who while speaking to the AGI press agency underlined “the importance of regenerative medicine, one of the great hopes for the future, as well as biotechnologies for new treatments altering molecular systems”.

The notification will expire on July 20 and is intended for universities, the National Research Council (CNR), and other private and public research groups. Three independent judges, one of whom will be from abroad, will evaluate the projects that are presented. The research topics eligible for funding include innovative strategies for experimental models (cellular and animal), risk/benefit analysis for pharmacological and non-pharmacological treatments and epidemiology research.

An allocation of three million euros for the next three years is planned to finance projects on rare diseases. No referral to embryonic stem cells, which are considered by many experts to be more promising in research because they are totipotent, or potentially able to become any type of cell, was made in the notice. “This was a choice,” specified Fazio, “that the Federal and Regional government conference made, which asked for a change to the original announcement, which was open also to stem cells.

Not mentioning them was a not a political choice by the health ministry, but a decision made by the federal and regional governments”. In any case, explained the deputy minister, “studying adult stem cells and their differentiation is more interesting to me and I believe that it is more advantageous”. There are numerous possibilities for treatments: “Not only ocular and cardiac diseases, Parkinson’s and rare diseases,” explained Fazio, “but also new possibilities to fight tumors.

Some researchers believe that tumor stem cells are the most aggressive stem cells of the tumor, and somehow determine the spread of the tumor. Tumor stem cell research could help understand the evolution of tumors and prevent their growth by striking their stem cells”. Financing, assured Fazio, “is in line with previous funding and in 2009 there will be funding for general research, open to all lines of research, therefore there will be funds available for stem cells.”

Incoming search terms:

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson’s disease. The technique could be developed for application in other degenerative conditions.

Drs Clare Parish and Lachlan Thompson lead the research from the Florey Neuroscience Institutes and the University of Melbourne. They are members of the newly established Stem Cells Australia collaboration launched at the University of Melbourne today.

Stem Cells Australia is a new $21m Australian Research Council Special Research Initiative bringing together Australia’s leading stem cell scientists.

Led by internationally renowned stem cell expert Professor Martin Pera and administered by the University of Melbourne, the Initiative links Australia’s leading experts in bioengineering, nanotechnology, stem cell biology, advanced molecular analysis and clinical research to solve some of the our biggest health challenges.

“Stem Cells Australia will not only play a major role in leading Australian research into stem cell science, it will help the Australian community to understand the impact of scientific breakthroughs in this fast-paced and fascinating field,” he said.

Opening Stem Cells Australia on behalf of Innovation Minister Senator Kim Carr, ARC Chief Executive Officer Professor Margaret Sheil said the Initiative would make an important contribution to life-changing research.

Incoming search terms: